PSMA PET/CT-targeted biopsy improves detection of clinically significant prostate cancer

A new study shows that PSMA PET/CT-targeted biopsy detects more clinically significant prostate cancer than systematic biopsy alone, especially in men with negative or inconclusive MRI findings but persistent clinical risk factors.

Why it matters. This breakthrough could help physicians identify clinically significant cancers more accurately, reducing unnecessary procedures and improving patient outcomes.